Candel Therapeutics presented new clinical and biomarker data at SITC 2026 showing systemic immune activation and improved survival outcomes for their cancer therapies aglatimagene and linoserpaturev. In localized prostate cancer, aglatimagene induced strong cytotoxic T-cell responses, supporting a planned FDA biologics license application. In non-small cell lung cancer, immune changes correlated with survival beyond 24 months, reinforcing ongoing phase 3 trials. Linoserpaturev showed durable survival in recurrent glioblastoma patients, with immune markers suggesting strategies to enhance treatment. These findings advance Candel's clinical programs and regulatory plans.
Candel Therapeutics clinical data is the subject, with this Pluang market snapshot for health stocks as of Nov 06, 2026 20:42 WIB: Out of 150 health-sector US stocks, 51 rose and 94 fell. Notable movers include HRTX at USD 0.29 (+3.54%), SNN at USD 30.91 (-3.44%), and SMMT at USD 14.65 (+3.24%). Typical hold times range from 18 to 123 days, with varied buy/sell activity.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
